BioTelemetry Inc (NASDAQ:BEAT)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $37.67 and last traded at $37.81, with a volume of 4711 shares changing hands. The stock had previously closed at $39.12.

A number of equities analysts recently weighed in on the stock. ValuEngine upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. TheStreet lowered shares of BioTelemetry from a “b-” rating to a “c+” rating in a research report on Friday, August 16th. Sidoti lowered their price objective on shares of BioTelemetry from $95.00 to $87.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Finally, Raymond James lowered shares of BioTelemetry from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $73.50.

The company has a market capitalization of $1.34 billion, a PE ratio of 19.38, a price-to-earnings-growth ratio of 2.01 and a beta of 1.37. The firm’s 50-day simple moving average is $40.63 and its 200 day simple moving average is $48.45. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.09 and a current ratio of 2.19.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.45 by $0.08. The company had revenue of $111.80 million for the quarter, compared to analyst estimates of $111.11 million. BioTelemetry had a net margin of 11.06% and a return on equity of 22.98%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.46 EPS. As a group, equities analysts anticipate that BioTelemetry Inc will post 1.97 earnings per share for the current year.

In other BioTelemetry news, SVP Peter Ferola sold 44,276 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total transaction of $1,728,092.28. Following the sale, the senior vice president now directly owns 19,622 shares in the company, valued at approximately $765,846.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Stephens Investment Management Group LLC boosted its position in shares of BioTelemetry by 42.4% in the 2nd quarter. Stephens Investment Management Group LLC now owns 668,530 shares of the medical research company’s stock worth $32,190,000 after buying an additional 199,171 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of BioTelemetry by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,698,176 shares of the medical research company’s stock worth $178,067,000 after buying an additional 195,534 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of BioTelemetry in the 2nd quarter worth about $9,199,000. Sio Capital Management LLC purchased a new stake in shares of BioTelemetry in the 2nd quarter worth about $7,413,000. Finally, Pembroke Management LTD boosted its position in shares of BioTelemetry by 77.7% in the 2nd quarter. Pembroke Management LTD now owns 334,381 shares of the medical research company’s stock worth $16,100,000 after buying an additional 146,181 shares in the last quarter. Institutional investors own 90.65% of the company’s stock.

BioTelemetry Company Profile (NASDAQ:BEAT)

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Featured Article: Quantitative Easing

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.